Compare BWB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWB | IVVD |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | 325 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.5M | 437.1M |
| IPO Year | N/A | 2021 |
| Metric | BWB | IVVD |
|---|---|---|
| Price | $17.52 | $1.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.33 | $8.75 |
| AVG Volume (30 Days) | 50.6K | ★ 1.8M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $24.57 | $143.48 |
| Revenue Next Year | $12.35 | $25.40 |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $11.93 | $0.46 |
| 52 Week High | $20.30 | $3.07 |
| Indicator | BWB | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 51.22 |
| Support Level | $15.98 | $1.41 |
| Resistance Level | $17.75 | $2.01 |
| Average True Range (ATR) | 0.68 | 0.11 |
| MACD | -0.18 | 0.04 |
| Stochastic Oscillator | 34.19 | 87.69 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.